Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibronectin leucine-rich transmembrane protein 1 (FLRT1) is a single-pass transmembrane protein that belongs to the FLRT family, sharing structural similarity with other small leucine-rich proteoglycans found in the extracellular matrix. FLRT1 is expressed predominantly in the brain and kidney. The protein plays important roles in both cell adhesion and receptor signaling, particularly by mediating interactions with fibroblast growth factor receptors (FGFR), which can activate MAP kinase signaling pathways and promote neurite outgrowth. FLRT1 is also implicated in the regulation of cell-cell adhesion and cell guidance through interactions with other surface molecules, including latrophilins (ADGRL1/LPHN1 and ADGRL3). Genetic variants in FLRT1 have been associated with neurological conditions, such as spastic paraplegia, optic atrophy, and neuropathies. No direct drug interactions, mechanisms of action for therapeutics, or clinical biomarker or safety concerns are currently reported in the main literature sources[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibronectin leucine-rich transmembrane protein 1 (FLRT1).